The Endocrine Society’s annual meeting, ENDO 2026, has convened in Chicago, Illinois, bringing together thousands of global experts to address the most pressing issues in hormone research and clinical practice. This premier global event serves as a nexus for endocrinologists, researchers, and healthcare professionals to share breakthrough discoveries and establish new standards for patient care. Among the most anticipated components of this year’s program are the high-stakes clinical debates, the release of pivotal clinical practice guidelines, and the recognition of international research excellence. As the field of endocrinology faces evolving challenges—ranging from the global obesity epidemic to the complexities of pediatric development—the sessions at ENDO 2026 are designed to provide clarity and foster consensus in areas where medical evidence remains in flux.
The Testosterone Controversy: Managing Hypogonadism in the Context of Obesity
One of the most heavily attended sessions at ENDO 2026 focused on the contentious intersection of metabolic health and male reproductive hormones. Moderated by Stephen Hammes, MD, PhD, a former president of the Endocrine Society, the debate titled "Low Testosterone in Obesity: Should We Treat or Not?" addressed a clinical dilemma that has grown increasingly common as obesity rates climb globally. The session featured a rigorous exchange between two prominent figures in the field: Franck Mauvais-Jarvis, MD, PhD, of the Tulane University School of Medicine, and David Handelsman, MBBS, PhD, FRACP, of the ANZAC Research Institute at the University of Sydney.
The debate centers on the phenomenon of functional hypogonadism, where obese men often present with low serum testosterone levels without an underlying organic pathology of the pituitary or testes. Dr. Mauvais-Jarvis argued for the "treat" side, suggesting that testosterone replacement therapy (TRT) can offer significant metabolic benefits, including improvements in insulin sensitivity and muscle mass, which may assist in breaking the cycle of weight gain and hormonal suppression. Conversely, Dr. Handelsman advocated for a more conservative approach, emphasizing that low testosterone in this population is often a symptom of obesity rather than its cause. He argued that weight loss and lifestyle modifications should remain the primary focus, as these interventions can naturally restore testosterone levels without the potential risks associated with long-term hormonal therapy.
Dr. Hammes noted that the absence of a specific, universally accepted standard of care for low testosterone in the setting of obesity makes this discussion vital. Current clinical data suggests that nearly 40% of obese men may have low total testosterone levels, yet the long-term cardiovascular and prostate safety of treating these individuals remains a subject of intense investigation. The debate highlighted the need for personalized medicine, where clinicians must weigh the immediate symptomatic relief of TRT against the long-term goal of metabolic recovery.
Establishing New Standards: The 2026 Clinical Practice Guideline for Central Precocious Puberty
A landmark moment of the conference occurred on Saturday, June 14, with the official publication and presentation of the "Central Precocious Puberty: An Endocrine Society Clinical Practice Guideline." Published in the Journal of Clinical Endocrinology & Metabolism (JCEM), these guidelines represent a comprehensive update to the management of children who begin puberty at an abnormally early age. Central Precocious Puberty (CPP) is characterized by the premature activation of the hypothalamic-pituitary-gonadal axis, which can lead to early bone maturation and reduced final adult height, as well as significant psychosocial stress for the child and their family.
The new guidelines, discussed in detail by senior authors and researchers, provide evidence-based recommendations on the diagnostic thresholds for CPP, the appropriate use of GnRH agonists (the gold-standard treatment), and the timing for the cessation of therapy. The update is particularly timely given the observed global trend of decreasing ages for the onset of puberty, a phenomenon that researchers believe may be linked to environmental factors, nutritional changes, and the rising prevalence of childhood obesity.
Data supporting the new guidelines indicate that early intervention can significantly improve height outcomes, but the guidelines also stress the importance of psychological support. The expert panel emphasized that treatment should not be universal for every child who meets the chronological criteria for early puberty; rather, it should be reserved for cases where there is evidence of rapid progression or significant distress. This nuanced approach aims to prevent the over-medicalization of pediatric development while ensuring that those in need receive timely and effective care.
International Collaboration and the Transatlantic Alliance Award
The global nature of endocrine research was highlighted through the presentation of the Transatlantic Alliance Award to Anna L. Gloyn, DPhil, FMedSci. This prestigious award, a collaboration between the Endocrine Society and the European Society of Endocrinology, recognizes individuals who have made significant contributions to the field through research conducted in both Europe and the United States. Dr. Gloyn, a renowned expert in the genetics of type 2 diabetes and pancreatic beta-cell function, shared her insights into how lab culture and international mobility influence scientific progress.
In an interview with Glenda Fauntleroy Shaw, Dr. Gloyn reflected on her career, which spanned influential roles in the United Kingdom and her current tenure in the United States. She noted that while the fundamental principles of molecular biology and genetics remain consistent across borders, the "culture of the bench" is often shaped by the principal investigator and the institutional environment. Dr. Gloyn’s work has been instrumental in identifying genetic variants that predispose individuals to diabetes, moving the field closer to precision medicine where treatments can be tailored to a patient’s specific genetic profile.
Her experiences underscore a broader theme of ENDO 2026: the necessity of global cooperation. The challenges of endocrine disorders—ranging from rare genetic conditions to pandemic-level metabolic diseases—do not respect national borders. Dr. Gloyn’s career serves as a blueprint for the next generation of researchers, demonstrating that the integration of diverse scientific perspectives is essential for solving complex biological puzzles.
Reflecting on a Legacy: Unforgettable Moments from ENDO’s Past
Beyond the clinical and scientific data, ENDO 2026 served as a venue for communal reflection. A special retrospective titled "Looking Back: Unforgettable Moments from ENDOs Past" featured testimonials from a dozen prominent endocrinologists who shared how previous annual meetings shaped their careers. For many, ENDO is not merely a conference but a pivotal life event. One future president of the Endocrine Society recalled that attending their first ENDO as a trainee was the deciding factor in pursuing a career in the specialty, citing the passion and intellectual curiosity of the community.
These narratives serve a functional purpose in the professional development of younger attendees. By documenting the history of the society and the evolution of the field, the retrospective provides context for current clinical practices. The memories shared range from the excitement of seeing the first results of landmark clinical trials to the networking opportunities that led to decades-long research collaborations. In Chicago, a city known for its rich medical history and architectural innovation, these reflections remind attendees that they are part of a continuous lineage of scientific inquiry.
Analysis of Implications for Future Practice
The developments at ENDO 2026 suggest a shifting paradigm in endocrinology. The debate over testosterone treatment in obesity reflects a broader move toward "metabolic-first" interventions, where the underlying weight issues are addressed as the primary driver of hormonal imbalance. This aligns with the emergence of new classes of medications, such as GLP-1 receptor agonists, which are revolutionizing the treatment of obesity and type 2 diabetes.
Furthermore, the new CPP guidelines indicate a growing sophistication in pediatric endocrinology. As diagnostic tools become more sensitive and our understanding of the "normal" range of pubertal onset evolves, the medical community is moving away from rigid age-based cutoffs toward a more holistic assessment of child health. This shift requires clinicians to be as adept at counseling and psychological assessment as they are at interpreting hormonal assays.
The recognition of leaders like Dr. Anna Gloyn also highlights the increasing importance of genetics and "big data" in endocrinology. As genomic sequencing becomes more accessible, the integration of these findings into routine clinical care will be the next great challenge for the field. The Transatlantic Alliance Award serves as a reminder that the infrastructure for this future must be built on international standards and collaborative data-sharing.
Chronology of Major Events at ENDO 2026
The conference followed a structured timeline designed to maximize engagement across different sub-specialties:
- June 11–12: Pre-conference workshops focused on advanced imaging techniques in endocrine oncology and the latest in continuous glucose monitoring (CGM) technology.
- June 13: The formal opening ceremony, followed by the "Low Testosterone in Obesity" debate, which set the tone for a conference focused on addressing "gray areas" in clinical medicine.
- June 14: The release of the Central Precocious Puberty Clinical Practice Guideline. This included a morning press conference followed by an afternoon "Meet the Professor" session where clinicians could ask specific questions about implementing the new recommendations.
- June 15: The Transatlantic Alliance Award lecture by Dr. Anna L. Gloyn, highlighting the future of genomic medicine in diabetes.
- June 16: Closing plenary sessions focusing on the impact of climate change on endocrine health and the official handover of leadership for the upcoming year.
Conclusion and Future Outlook
As ENDO 2026 concludes in Chicago, the impact of the sessions will likely be felt in clinics and laboratories for years to come. The conference succeeded in highlighting that while endocrinology is a field rooted in precise measurements and biochemical pathways, its application requires a deep understanding of human behavior, societal trends, and international collaboration.
The Endocrine Society remains a central authority in navigating these complexities. By providing a platform for rigorous debate and the dissemination of high-quality guidelines, the society ensures that its members are equipped to handle the challenges of a rapidly changing medical landscape. Whether it is deciding when to treat a patient with low testosterone or how to manage a child’s early development, the insights gained at ENDO 2026 provide a vital roadmap for improving patient outcomes globally.
For those unable to attend in person, the society continues to provide resources and story suggestions through its official publication, Endocrine News, ensuring that the knowledge shared in Chicago reaches the widest possible audience. The ongoing dialogue between researchers and clinicians remains the hallmark of the society, driving the field toward a future where hormonal health is optimized for all populations.
